頭孢噻肟
| 中文名稱 | 頭孢噻肟 |
|---|---|
| 中文同義詞 | 頭孢氨噻;頭孢氨噻肟;頭孢噻肟;頭孢噻肟酸;頭孢噻肟雜質(zhì);噻胞霉素;頭孢噻肟酸(中間體);3-乙酰氧基甲基-7-[2-(2-氨基-4-噻唑基)-2-甲氧亞胺基]-乙酰胺基-3-頭孢-4-羧酸 |
| 英文名稱 | Cefotaxime |
| 英文同義詞 | Cefotaxime;Cefotaxima acid;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-;Cefabol;(6R)-3-(Acetoxymethyl)-7α-[[(2-amino-4-thiazolyl)[(Z)-methoxyimino]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(6R,7R)-7α-[2-(2-Amino-4-thiazolyl)-2-[(Z)-methoxyimino]acetylamino]-3-(acetoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;Zariviz;(6R,7R)-3-[(acetyloxy)Methyl]-7-[(2E)-2-(2-aMino-1,3-thiazol-4-yl)-2-(MethoxyiMino)acetaMido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| CAS號(hào) | 63527-52-6 |
| 分子式 | C16H17N5O7S2 |
| 分子量 | 455.47 |
| EINECS號(hào) | 264-299-1 |
| 相關(guān)類別 | 醫(yī)藥標(biāo)準(zhǔn)品;雜質(zhì)對(duì)照品;中間體;醫(yī)藥化工類;原料中間體-原料藥;對(duì)照品-雜質(zhì)對(duì)照品;醫(yī)藥原料;Pharmaceutical intermediate;原料;原料藥;化工中間體工業(yè)原料;醫(yī)藥、農(nóng)藥及染料中間體;雜質(zhì)對(duì)照品;有機(jī)化工原料;抗生素類;化學(xué)試劑;工業(yè)化 |
| Mol文件 | 63527-52-6.mol |
| 結(jié)構(gòu)式 | ![]() |
頭孢噻肟 性質(zhì)
| 熔點(diǎn) | >158°C (dec.) |
|---|---|
| 密度 | 1.80±0.1 g/cm3(Predicted) |
| 儲(chǔ)存條件 | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| 溶解度 | 可溶于DMSO(少許)、甲醇(少許) |
| 酸度系數(shù)(pKa) | pKa 2.1 (H2O t=20.0 I<0.005 ) (Uncertain);3.4(H2O t=20.0 I<0.005 ) (Uncertain);10.9(H2O t=20.0 I<0.005 ) (Uncertain) |
| 形態(tài) | 固體 |
| 顏色 | 白色至類白色 |
| 穩(wěn)定性 | 吸濕性 |
| 主要應(yīng)用 | 藥物(小分子) |
| InChIKey | GPRBEKHLDVQUJE-QSWIMTSFSA-N |
| SMILES | N12[C@@]([H])([C@H](NC(/C(/C3=CSC(N)=N3)=N\OC)=O)C1=O)SCC(COC(C)=O)=C2C(O)=O |
| LogP | 1.2 |
| CAS 數(shù)據(jù)庫(kù) | 63527-52-6(CAS DataBase Reference) |
| EPA化學(xué)物質(zhì)信息 | 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)- (63527-52-6) |
Cefotaxime exhibits an MIC of 0.0625 mg/L for
V. vulnificus
CMCP6.
The combination of ciprofloxacin and cefotaxime is more effective in clearing
V. vulnificus
in vivo than previously used regimens.
| Animal Model: | Female, specific pathogen free, 8-week-old BALB/c mice. |
| Dosage: | 30 mg/kg. |
| Administration: | IP every 6 h. |
| Result: | The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each). |
安全信息
| WGK Germany | WGK 3 |
|---|---|
| RTECS號(hào) | XI0240000 |
| 海關(guān)編碼 | 29419000 |
| 存儲(chǔ)類別 | 11 - 可燃固體 |
頭孢噻肟 化學(xué)藥品說明書
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2026/07/06 | S4720 | 頭孢噻肟酸 Cefotaxime | 63527-52-6 | 25mg | 794.77元 |
| 2026/06/05 | HY-A0088AR | 頭孢噻肟酸 Cefotaxime (Standard) | 63527-52-6 | 10 mg | 333元 |
